Anti-ITB3/ ITGB3/ BDPLT16 monoclonal antibody

Anti-ITB3/ ITGB3/ BDPLT16 antibody for FACS & in-vivo assay

Target products collectionGo to ITGB3/ITGB3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T26457-Ab-1/ GM-Tg-hg-T26457-Ab-2Anti-Human ITGB3 monoclonal antibodyHuman
GM-Tg-rg-T26457-Ab-1/ GM-Tg-rg-T26457-Ab-2Anti-Rat ITGB3 monoclonal antibodyRat
GM-Tg-mg-T26457-Ab-1/ GM-Tg-mg-T26457-Ab-2Anti-Mouse ITGB3 monoclonal antibodyMouse
GM-Tg-cynog-T26457-Ab-1/ GM-Tg-cynog-T26457-Ab-2Anti-Cynomolgus/ Rhesus macaque ITGB3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T26457-Ab-1/ GM-Tg-felg-T26457-Ab-2Anti-Feline ITGB3 monoclonal antibodyFeline
GM-Tg-cang-T26457-Ab-1/ GM-Tg-cang-T26457-Ab-2Anti-Canine ITGB3 monoclonal antibodyCanine
GM-Tg-bovg-T26457-Ab-1/ GM-Tg-bovg-T26457-Ab-2Anti-Bovine ITGB3 monoclonal antibodyBovine
GM-Tg-equg-T26457-Ab-1/ GM-Tg-equg-T26457-Ab-2Anti-Equine ITGB3 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T26457-Ab-1/ GM-Tg-hg-T26457-Ab-2; GM-Tg-rg-T26457-Ab-1/ GM-Tg-rg-T26457-Ab-2;
GM-Tg-mg-T26457-Ab-1/ GM-Tg-mg-T26457-Ab-2; GM-Tg-cynog-T26457-Ab-1/ GM-Tg-cynog-T26457-Ab-2;
GM-Tg-felg-T26457-Ab-1/ GM-Tg-felg-T26457-Ab-2; GM-Tg-cang-T26457-Ab-1/ GM-Tg-cang-T26457-Ab-2;
GM-Tg-bovg-T26457-Ab-1/ GM-Tg-bovg-T26457-Ab-2; GM-Tg-equg-T26457-Ab-1/ GM-Tg-equg-T26457-Ab-2
Products NameAnti-ITGB3 monoclonal antibody
Formatmab
Target NameITGB3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-ITGB3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-542Pre-Made Tadocizumab biosimilar, Fab, Anti-ITGA2B;ITGB3 Antibody: Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 therapeutic antibody
    BiosimilarGMP-Bios-ab-195Pre-Made Etaracizumab biosimilar, Whole mAb, Anti-ITGAV;ITGB3 Antibody: Anti-CD51/MSK8/VNRA/VTNR;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 therapeutic antibody
    BiosimilarGMP-Bios-ab-276Pre-Made Intetumumab biosimilar, Whole mAb, Anti-ITGAV;ITGB3 Antibody: Anti-CD51/MSK8/VNRA/VTNR;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 therapeutic antibody
    BiosimilarGMP-Bios-INN-713Pre-Made Abciximab Biosimilar, Fab Fusion, Anti-Itga2B/Itgb3 Antibody: Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species ITB3/ ITGB3/ BDPLT16 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMAAV000255human ITGB3 AAV plasmid
    ORF Viral VectorvGMAAV000255human ITGB3 AAV particle
    ORF Viral VectorpGMAD000543house mouse Itgb3 Adenovirus plasmid
    ORF Viral VectorvGMAD000543house mouse Itgb3 Adenovirus particle


    Target information

    Target IDGM-T26457
    Target NameITGB3
    Gene ID3690,16416,29302,717379,403788,101092159,282642,100009709
    Gene Symbol and SynonymsBDPLT16,BDPLT2,BDPLT24,CD61,GP3A,GPIIIa,GT,GT2,INGRB3,INTB3,ITGB3
    Uniprot AccessionP05106,Q8R2H2
    Uniprot Entry NameITB3_HUMAN,ITB3_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, INN Index
    DiseaseProstate Cancer, Kidney transplant rejection
    Gene EnsemblENSG00000259207
    Target ClassificationN/A

    The target: ITGB3, gene name: ITGB3, also named as BDPLT16, BDPLT2, CD61, GP3A, GPIIIa, GT. The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.